A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...
Gilead Sciences (NASDAQ:GILD) traded higher in the morning hours Thursday after announcing that a Phase 3 trial for its experimental therapy lenacapavir succeeded when used as a twice-yearly option to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results